FCGR2A and autoimmune thrombocytopenic purpura: Additional evidence that FcγR-mediated pathways are important in ITP pathogenesis was shown by the therapeutic use of IVIg, which may bind FcγRs by its Fc-portion (205), and is one of the successful cornerstone treatments for ITP to rapidly increase platelet counts.